Physician profile
Mary C Yoder
NPI 1346217312
$3,260.88
in general payments reported to CMS, 2019-2025
42 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $177 · 2021: $627 · 2022: $499 · 2023: $611 · 2024: $626 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,654.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $828.23 | 2021-2025 | Vraylar, Viberzi, Qulipta |
| Novo Nordisk INC | $436.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $191.24 | 2019-2025 | Jardiance, Zepbound, Emgality |
| Pfizer INC. | $152.91 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.13 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $109.49 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $105.66 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $104.83 | 2019-2025 | Repatha, Otezla, Otezla |
| Supernus Pharmaceuticals, INC. | $85.27 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.26 | 2019-2025 | Jardiance |
| Allergan, INC. | $69.95 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $67.60 | 2019-2022 | |
| Shield Therapeutics INC | $55.15 | 2023 | Accrufer |
| Biogen, INC. | $54.54 | 2021-2025 | Zurzuvae |
| Glaxosmithkline, LLC. | $54.53 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Yoder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.